Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AP31969 in Healthy Subjects
NCT06066099Phase 1Completed
- Sponsor
- Acesion Pharma
- Start
- Oct 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AP31969 in Atrial fibrillation (AFib) (3 arms), sponsored by Acesion Pharma. Primary endpoint: Number of Participants who Experienced an Adverse Event up to 48 days. Started Oct 2023; status: completed.
02
Drugs
AP31969
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06066099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066099.